Trial Profile
Phase IIA, Multicenter, Randomized, Third-Party Unblinded, Adjuvant And Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of ACC-001 And QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2016
Price :
$35
*
At a glance
- Drugs QS 21 (Primary) ; Vanutide cridificar (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00498602).
- 09 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT00498602).
- 09 May 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov (Parent trial: NCT00498602).